SBH Diagnostics

 
 
-
-

NEWS RELEASE

FOR IMMEDIATE DISTRIBUTION

 

SBH Diagnostics has become a Corporate Sponsor of the Sjogren's Syndrome Foundation

         (Natick, MA)  August 1, 2013. SSFSBH Diagnostics has become a corporate sponsor of the Sjogren's Syndrome Foundation (SSF).

This alliance will provide for a synergy assist with the corporate mission of the Sjogren's Syndrome Foundation:

 "To shorten the time to diagnose Sjögren's by 50% in 5 years!"

To this end, SBH Diagnostic is developing a new and ultra-sensitive early detection Sjogren's diagnostics test. This test called EASy Sjogren's will be offered under the auspices of a CLIA Lab test.

Initial test results show a 3-fold increase in the specificity and sensitivity over existing Sjogren's blood tests. The test will provide results within 72 hours after receipt of a sample!

SBHD Diagnostics is now enlisting clinicians, patients and Pharmaceutical Companies to provide validation samples. SBH Diagnostics plans the commercialized offer of the test within 2 months under CLIA Certification.

According the Sjogren's Syndrome Foundation:

Sjögren's is a chronic autoimmune disease in which people's white blood cells attack their moisture-producing glands. Today, as many as four million Americans are living with this disease.

Although the hallmark symptoms are dry eyes and dry mouth, Sjögren's may also cause dysfunction of other organs such as the kidneys, gastrointestinal system, blood vessels, lungs, liver, pancreas, and the central nervous system. Patients may also experience extreme fatigue and joint and muscle pain and have a higher risk of developing lymphoma.

With upwards of 4,000,000 Americans suffering from Sjögren's, it is one of the most prevalent autoimmune disorders. Nine out of 10 patients are women. About half of the time Sjögren's occurs alone, and the other half it occurs in the presence of another autoimmune connective tissue disease such as rheumatoid arthritis, lupus, or scleroderma.

Since symptoms of Sjögren's mimic other conditions and diseases, Sjögren's can often be overlooked or misdiagnosed. On average, it takes nearly 4.7 years to receive a diagnosis of Sjögren's. Patients need to remember to be pro-active in talking with their physicians and dentists about their symptoms and potential treatment options. Since the disease was first identified in 1933 by Dr. Henrik Sjögren, it has been proven to affect virtually every racial and ethnic group.

The SBH Diagnostic Sjogren's Test will be able to discern Sjogren's from other auto-immune diseases and serve as definitive diagnostics basis is for Sjogren's identification.

SBH Diagnostics is looking for partners to validate patient samples with other autoimmune diseases, as well to collaborate with pharmaceutical / biotechnology companies currently conducting Sjogren's clinical trials and drug development.  In addition, we are looking for diagnostics distributors in Canada, Europe, South America, India, China, and other countries.

For further information, sampling inquires and test data please contact:

Marvin A. Collin,
Vice President Business Development
macollin@sbhdiagnostics.com
617-680-9792


-
-
- - -


Contract Research Organization and CLIA Lab
(508) 650-6218 | Info@SBHdiagnostics.com